Lipocine Inc. Operating Income Loss

• Lipocine Inc. showed a decrease of -797.9% in Operating Income Loss from 2024 to 2025.
• This data is from Lipocine Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Lipocine Inc.'s Operating Income Loss has declined by 367.5%.
• Historical annual values: Fiscal year 2025: -$10.37 million | Fiscal year 2024: -$1.16 million | Fiscal year 2023: -$17.93 million | Fiscal year 2022: -$12.12 million | Fiscal year 2021: $3.15 million | Fiscal year 2020: -$18.00 million | Fiscal year 2019: -$12.90 million | Fiscal year 2018: -$11.33 million | Fiscal year 2017: -$21.22 million | Fiscal year 2016: -$19.19 million | Fiscal year 2015: -$18.38 million | Fiscal year 2014: -$20.48 million | Fiscal year 2013: -$10.68 million | Fiscal year 2012: $3.88 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026